Sakar Healthcare Limited has informed the Exchange regarding Appointment of Ms Megha Samdani as Independent Director of the company w.e.f. July 25, 2025 subject to approval of members/shareholders of the Company.
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sakar Healthcare's board held a meeting on July 25, 2025, and approved the unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26), along with convening the 21st Annual General Meeting on September 23, 2025 via video conferencing. The board appointed three new Independent Directors — Ms. Megha Samdani, Ms. Reeya Kothari, and Ms. Hiral Patel — each for a five-year term, subject to shareholder approval. M/s. Nishant Pandya & Associates was appointed as Secretarial Auditor for five years (FY 2025-26 to FY 2029-30), and M/s. Dalwadi & Associates was reappointed as Cost Auditor for FY 2025-26. Additionally, three senior management personnel were appointed: Mr. Sudhir Ghule as COO, Mr. Raviraj Karia as SVP (Finance & Accounts), and Mr. Nimesh Suthar as SVP (International Business), all effective July 25, 2025. The new hires bring strong pharma industry experience from companies like Zydus, Cipla, Sun Pharma, Lupin, Dr. Reddy's, Baxter, and Intas.
The addition of three Independent Directors and experienced senior management (especially in international business and operations) signals the company's intent to strengthen governance and scale globally. Shareholders should watch the Q1 FY26 results for the financial impact and the AGM on September 23 for approving these appointments.